XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its ...
July 10 2019 - 8:00AM
XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research
Pioneer in Inflammation and Cardiovascular Disease, to its
Corporate Board
XBiotech Inc. (NASDAQ: XBIT) announced today that Peter Libby,
M.D., has been appointed to the Company’s Corporate Board of
Directors. Dr. Libby has played a pioneering role in
discovering how inflammation leads to cardiovascular disease. Dr.
Libby is a practicing cardiovascular specialist at Brigham and
Women’s Hospital in Massachusetts and he is Mallinckrodt Professor
of Medicine at Harvard Medical School.
Dr. Libby leads a research group at Harvard
Medical School and the Brigham and Women’s Hospital, which recently
discovered a novel mechanism by which interleukin-1 alpha (IL-1⍺)
may lead to heart attack and stroke. XBiotech’s anti-inflammatory
drug, bermekimab, blocks the action of IL-1⍺ and has been granted
fast track approval by the FDA in cardiovascular medicine.
Dr. Libby commented, “I have a long-term
interest in inflammation in cardiovascular diseases, and in novel
therapies to address this and other diseases, including
cancer. Targeting pro-inflammatory cytokines offers
considerable promise, and I look forward to helping XBiotech
translate advances in inflammation biology to the clinic.”
Dr. Libby has authored over 400 original
publications in peer reviewed journals and is Editor of the leading
textbook of cardiovascular medicine, Braunwald’s Heart
Disease. A recent publication from Dr. Libby’s laboratory
described for the first time a potential role of IL-1⍺ in the
formation of blood clots that lead to heart attack or stroke. These
findings suggest a possible therapeutic role for bermekimab to
limit injury related to heart attack and stroke.
John Simard, XBiotech’s President & CEO,
stated, “Dr. Libby is at the forefront of inflammation biology and
cardiovascular medicine. He has played leading roles in elucidating
mechanisms behind some of the most prominent drugs in medicine. Dr.
Libby will bring important perspective to XBiotech’s board.”
About Peter Libby, M.D. Peter
Libby, MD, is a cardiovascular specialist at Brigham and Women’s
Hospital in Boston, Massachusetts, and holds the Mallinckrodt
Professorship of Medicine at Harvard Medical School (HMS).
His areas of clinical expertise include general and
preventive cardiology. His current major research focus is the role
of inflammation in vascular diseases such as atherosclerosis.
Dr. Libby has a particular devotion to translate his basic
laboratory studies to pilot and then large-scale clinical
cardiovascular outcome trials. Dr. Libby is continually named a top
cardiologist. His research has received funding from the American
Heart Association and National Institutes of Health. Dr. Libby has
received world-wide research recognitions including the highest
research awards from the American Heart Association and American
College of Cardiology, the Gold Medal of the European Society of
Cardiology, the Anitchkow award from the European Atherosclerosis
Society, The Ernst Jung Gold Medal for Medicine, and the Earl
Benditt award for vascular biology. The author of well over 400
original peer-reviewed publications, over 500 reviews, chapters, or
other publications, Dr. Libby also serves as an Editor of the
leading textbook of cardiovascular medicine Braunwald’s Heart
Disease. Dr. Libby earned his medical degree at the University of
California, San Diego, and completed his training in internal
medicine and cardiology at the Peter Bent Brigham Hospital (now
Brigham and Women’s Hospital). He also holds an honorary MA degree
from Harvard University, and honorary doctorates from the
University of Lille and Université Laval.
About True Human™ Therapeutic
AntibodiesXBiotech’s True Human™ antibodies are derived
without modification from individuals who possess natural immunity
to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech’s True Human antibodies have the
potential to harness the body’s natural immunity to fight disease
with increased safety, efficacy and tolerability.
About XBiotech XBiotech is
a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of
therapeutic antibodies based on its True Human™ proprietary
technology. XBiotech currently is advancing a robust pipeline of
antibody therapies to redefine the standards of care in oncology,
inflammatory conditions and infectious diseases. Headquartered in
Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies
urgently needed by patients worldwide. For more information, visit
www.xbiotech.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements, including declarations regarding management's beliefs
and expectations that involve substantial risks and uncertainties.
In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes,"
"estimates," "predicts," "projects," "intend" or "continue" or the
negative of such terms or other comparable terminology, although
not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. These risks and
uncertainties are subject to the disclosures set forth in the "Risk
Factors" section of certain of our SEC filings. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
ContactAshley
Oteroaotero@xbiotech.com512-386-2930
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024